Venetoclax and acute myeloid leukaemia: an expanding new frontier
Venetoclax and acute myeloid leukaemia: an expanding new frontier
Venetoclax is an inhibitor of the anti-apoptotic B-cell lymphoma-2 (BCL-2) protein that has revolutionised the management of acute myeloid leukaemia in the past 5 years. Venetoclax in combination with azacitidine has become the new standard of care for the majority of patients with acute myeloid leukaemia who are ineligible for intensive chemotherapy due to age, fitness, or comorbidities. 1 Venetoclax has improved outcomes for this patient population and represents a valuable new treatment option in this setting. There is now interest in studying venetoclax combined with other acute myeloid leukaemia treatment regimens, including intensive chemotherapy.
Kieran D Sahasrabudhe , Alice S Mims.
© 2022 Elsevier Ltd. All rights reserved.
